cemiplimab (Libtayo) is an anti-pd1 immunotherapy indicated for the treatment of patients with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. This drug is an immune checkpoint inhibitor that targets PD-1, a protein on immune system cells (called T cells), that normally helps keep these cells from attacking other cells in the body. By blocking PD-1, this drug boosts the immune response restoring antitumor activity. cemiplimab (Libtayo) is given as an intravenous (IV) infusion.
- for more information visit Sanofi Genzyme Canada
The most common adverse reactions from this drug include fatigue, rash, and diarrhea. It’s very important to report any new side effects during or after treatment to your health care team promptly.
Provincial Funding Summary
Health Canada issues Notice of Compliance with Conditions (NOC/c) for Libtayo (cemiplimab), the first and only biologic for the treatment of advanced cutaneous squamous cell carcinoma (cSCC).
Learn about treatments available in Canada for cSCC patients. Click Here
Cutaneous Squamous Cell Carcinoma (cSCC) Patient Forum
Ask questions or learn from others. Join our online patient community by visiting MNC cSCC forum